Trump administration sues drugmaker Gilead Sciences over patent on Truvada for HIV prevention; The Washington Post, November 7, 2019

Christopher Rowland, The Washington Post; Trump administration sues drugmaker Gilead Sciences over patent on Truvada for HIV prevention

"The Trump administration took the rare step Wednesday of filing a patent infringement lawsuit against pharmaceutical manufacturer Gilead Sciences over sales of Truvada for HIV prevention, a crucial therapy invented and patented by Centers for Disease Control researchers."

UC open access fight exposes publishing rip-off: Charging exorbitant fees for journal articles isn’t in the best interests of scientific research, Mercury News, March 6, 2019

MERCURY NEWS & EAST BAY TIMES EDITORIAL BOARDS; Editorial: UC open access fight exposes publishing rip-off

Charging exorbitant fees for journal articles isn’t in the best interests of scientific research

"The scholarly research publishing industry is a rip-off that hinders scientific advances and piles unnecessary costs onto taxpayers who already fund much of the academic work.

It’s ridiculous that, in this age of the internet, researchers are paying huge fees for access to academic papers and for publication of their own work. That made sense in the days when scholarly works were printed in bound volumes. Today, academic work, especially public- and foundation-funded research, should be open for all. It shouldn’t cost $35 to $40 for each article, effectively freezing out those without the means to pay...

The University of California’s mission statement reads: “The distinctive mission of the university is to serve society as a center of higher learning, providing long-term societal benefits through transmitting advanced knowledge, discovering new knowledge, and functioning as an active working repository of organized knowledge.”

UC’s commitment to open access helps fulfill that goal and advances scientific enterprise for the benefit of all."

Who Gets to Read the Research We Pay For?; Slate, August 21, 2018

Aaron Mak, Slate; Who Gets to Read the Research We Pay For?: Scientific journals’ lock on new studies has ignited tension for years. When it comes to access for people with rare diseases, it becomes an ethical issue too.

"This does not sit well with academics and other members of the research community, who often publicly complain about the company’s profit margins, its allegedly restrictive copyrights, and the fact that much of the research it sells access to is taxpayer-funded. This public outrage seems to have gotten under the skin of William Gunn, Elsevier’s director of scholarly communications. When one user argued that people in rare-disease families “shouldn’t have to jump through additional hoops to access information,” Gunn responded, “Yes, everyone should have rainbows, unicorns, & puppies delivered to their doorstep by volunteers. Y’all keep wishing for that, I’ll keep working on producing the best knowledge and distributing it as best we can.”

This is just one reckless tweet in the heat of a Twitter spat (though it’s worth bearing Gunn’s job title in mind), and, sure, he later apologized. But the issue of rare-disease families trying to avoid the high fees associated with accessing research on potential treatments goes beyond this Twitter spat: It’s a real problem that has not been adequately fixed by the company."